Tesamorelin for Women: What the Evidence Covers and What It Doesn't

Short answer

Tesamorelin (brand Egrifta) is approved in the US to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, women and men alike. There has never been a women-only trial. In the two phase 3 trials 84% to 86% of participants were men, so what is known about women comes from small subgroups and a few other studies. The label rules it out in pregnancy and advises against breastfeeding, and growth hormone can change how the body clears sex hormones. For anyone else, including women looking at it for menopause belly fat, use is off-label and the evidence is thin. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.

How many women were in the research

Most of what is known about tesamorelin comes from people with HIV, and most of them were men. Last reviewed October 19, 2026.

Menopause, estrogen and belly fat

Many searches for tesamorelin for women are really about the belly fat that often builds after menopause. Growth hormone output falls with age, and estrogen appears to help keep it up. In a Mayo Clinic study with estradiol held at the same level, postmenopausal women's growth hormone responses to GHRH and other stimuli were only 26% to 33% of those in premenopausal women (Veldhuis 2007). When the same group cut estrogen further in 60 postmenopausal women, growth hormone rebound fell, and lower rebound went with more visceral fat on CT (Veldhuis 2016).

Neither study tested tesamorelin. They explain why the idea appeals, but no trial has shown that tesamorelin treats menopausal weight gain, and it is not approved for that. A trial in adults without HIV (Makimura 2012, 60 abdominally obese adults with low growth hormone) found less visceral fat and lower triglycerides over 12 months, with no change in the fat under the skin. Menopause symptoms and hormone therapy are a conversation for a clinician; see peptides for menopause for what the wider peptide evidence looks like.

Pregnancy, breastfeeding and fertility

What the Egrifta WR prescribing information (DailyMed, revised March 2025) says:

• —Pregnancy: contraindicated. Visceral fat normally rises in pregnancy, and the label says changing it offers no benefit and could harm the baby; in rats, exposure during pregnancy caused hydrocephaly in offspring. The label says to stop if pregnancy occurs.
• —Breastfeeding: the label says mothers using it should not breastfeed, both because of HIV transmission and the potential for serious reactions in a nursing infant.
• —Fertility: rats showed no effect on fertility at exposures about equal to the clinical one. The label describes no human fertility study.

Birth control, hormone therapy and other medicines

Tesamorelin works by raising your own growth hormone. The label notes that growth hormone may change the clearance of medicines broken down by liver CYP450 enzymes, naming sex steroids, corticosteroids, anticonvulsants and cyclosporine, and tells prescribers to watch for interactions. Sex steroids include the hormones in birth control and menopause hormone therapy, so anyone on them has a reason to tell the prescriber. People on glucocorticoid replacement for adrenal insufficiency may need it increased, according to the label. No study we found measured these interactions in women specifically.

Side effects in women

The label does not split side effects by sex. In the trials overall, the main ones were injection-site reactions, joint pain, swelling from fluid retention, tingling or numbness, carpal tunnel symptoms, higher blood sugar and allergic reactions; full figures are on tesamorelin side effects. In Baker 2012, the one study where most participants were women, side effects were reported by 68% on tesamorelin vs 36% on placebo and more often by women than men; 11 of the 13 people whose treatment had to be adjusted because of side effects were women. Most side effects were mild.

What women report here

Very few tesamorelin confessions say the writer is a woman, and both that do describe a stack with retatrutide, an unapproved triple agonist, so the tesamorelin part cannot be separated out. #775, a woman in her late sixties, alternates tesamorelin with other growth hormone peptides alongside retatrutide and describes some body recomposition and lost inches while her weight has stalled for a month; she also mentions a raised heart rate on retatrutide. #827, a woman in her thirties, describes a large weight loss over seven months on retatrutide plus tesamorelin and being able to race her daughter to the car. A large scale drop is most likely the GLP-1-type drug, since the tesamorelin label calls it weight neutral. These are two anonymous stories, not evidence. The tesamorelin hub has every report.

Realistic expectations

In the trials, tesamorelin shrank deep belly fat over about six months and the effect faded after stopping (tesamorelin results). The label calls it weight neutral and says it is not for weight loss, and long-term heart and blood vessel safety has not been established. It is ruled out in active cancer and when the hypothalamic-pituitary axis is disrupted. WADA bans GHRH analogues, including tesamorelin, for tested athletes. Products sold online as "research" tesamorelin are not the approved drug. Anyone considering it, especially with a pregnancy possible, a cancer history or diabetes, should start with a clinician.